Advances in vivo imaging of PD-L1 by Immuno-PET
-
摘要: ：免疫正电子发射计算机断层显像（Immuno-PET）是一种高效特异性，无创性和活体即时成像的诊断技术。这种技术不仅能可视化活体肿瘤细胞的定位，并且可识别肿瘤免疫受体（如PD-L1）并进行分子量化。PD-L1的靶向成像和预后评价方面具有巨大的发展前景。近年来，Immuno-PET在PD-L1靶向活体成像方面的研究逐渐成为热点。本文就Immuno-PET活体表征PD-L1的原理、应用价值、常用核素、新型示踪剂性质以及其在活体动物、人体上的成像效果等方面作一综述。
-
关键词:
- 免疫正电子发射计算机断层显像 /
- 程序性细胞死亡受体配体1 /
- 肿瘤免疫 /
- 活体分子成像 /
- 同位素示踪剂
Abstract: Immuno-positron emission tomography (Immuno-PET) is high efficient, noninvasive technique to in vivoimaging. This technique can not only visualize the tumor location, but also identify and quantify the changes of tumor immunological receptor (such as PD-L1). It has a promising prospect in programmed death ligand 1 (PD-L1) targeted imaging and evaluation on prognosis. In recent years, immuno-PET in PD-L1-targeted in vivo imaging becomes a hotspot in research. This review would summarize the principle of various new PD-L1 probes, application, common nuclides, properties of novel molecular tracers, imaging effects of immuno-PET in vivo(animal and human body).-
Key words:
- Immuno-PET /
- PD-L1 /
- tumor immunity /
- in vivo molecular imaging /
- isotopic indicator
-
表 1 几种新型表征PD-L1的immuno-PET示踪剂性质
Table 1. Properties of several novel PD-L1tracers of immuno-PET (Mean±SD)
名称 与PD-L1解离常数（nmol/L） 动物模型最佳T/B比值与到达时间 动物模型最佳T/M比值与到达时间 放射性化学纯度（%） 参考文献 IgG型示踪剂 89Zr-C4 人4.2±0.7 ** ** > 98 [29] 89Zr-DFO-6E11 鼠0.23 41.94±1.84（144 h） 10.74±1.49（144 h） > 99 [33] [64Cu]Atezolizumab 鼠0.13、人0.43 ** 13.2±0.9（48 h） > 96 [35] 98Zr-DFO-PD-L1Mab 鼠≈0.3 ** 48（2 d） > 95 [34] 单域抗体示踪剂 68Ga-NOTA-Nb109 鼠2.9 5.48±0.12（1 h） 9.33±0.82（1 h） > 98 [42] 89Zr-Df-KN035 鼠2.86±0.23 0.5±0.05（24 h） 7.70±1.37（120 h） > 98 [16] 肽段示踪剂 [64Cu]WL12 ** 4.7±1.2（1 h） 25.6±1.9（1 h） > 95 [44] [68Ga]WL12 ** 7.56±16.47（1 h） 100.47±61.23（2 h） > 99 [43] **无文献报道的数据; T/B: 肿瘤血液比; T/M: 肿瘤肌肉比; Immuno-PET: 免疫正电子发射计算机断层显像. 
下载: 导出CSV
-
[1] Wei W, Rosenkrans ZT, Liu J, et al. ImmunoPET: concept, design, and applications[J]. Chem Rev, 2020, 120(8): 3787-851. doi: 10.1021/acs.chemrev.9b00738 [2] Teng FF, Meng XJ, Kong L, et al. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: a systematic review[J]. Cancer Lett, 2018, 414: 166-73. doi: 10.1016/j.canlet.2017.11.014 [3] Bahce I, Yaqub M, Smit EF, et al. Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET[J]. Lung Cancer, 2017, 107: 1-13. doi: 10.1016/j.lungcan.2016.05.025 [4] Emens LA, Ascierto PA, Darcy PK, et al. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape[J]. Eur J Cancer, 2017, 81: 116-29. doi: 10.1016/j.ejca.2017.01.035 [5] Du Y, Liang XL, Li Y, et al. Nuclear and fluorescent labeled PD-1- liposome-DOX-64Cu/IRDye800CW allows improved breast tumor targeted imaging and therapy[J]. Mol Pharm, 2017, 14(11): 3978-86. doi: 10.1021/acs.molpharmaceut.7b00649 [6] Hettich M, Braun F, Bartholomä MD, et al. High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers[J]. Theranostics, 2016, 6(10): 1629-40. doi: 10.7150/thno.15253 [7] Bailly C, Cléry PF, Faivre-Chauvet A, et al. Immuno-PET for clinical theranostic approaches[J]. Int J Mol Sci, 2016, 18(1): E57. doi: 10.3390/ijms18010057 [8] Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology[J]. J Clin Oncol, 2012, 30(31): 3884-92. doi: 10.1200/JCO.2012.42.4887 [9] Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges[J]. Nucl Med Commun, 2008, 29(3): 193-207. doi: 10.1097/MNM.0b013e3282f3a515 [10] Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in radioimmunotherapy[J]. J Nucl Med, 2005, 46(Suppl 1): 164S-71S. http://europepmc.org/abstract/MED/15653665 [11] Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in immunity and diseases[J]. Curr Top Microbiol Immunol, 2017, 410: 75-97. http://www.ncbi.nlm.nih.gov/pubmed/28929192 [12] Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy[J]. Lancet Oncol, 2016, 17(12): e542-e551. doi: 10.1016/S1470-2045(16)30406-5 [13] Wang X, Teng FF, Kong L, et al. PD-L1 expression in human cancers and its association with clinical outcomes[J]. Onco Targets Ther, 2016, 9: 5023-39. doi: 10.2147/OTT.S105862 [14] Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066): 255-65. doi: 10.1016/S0140-6736(16)32517-X [15] Shukuya T, Carbone DP. Predictive markers for the efficacy of antiPD-1/PD-L1 antibodies in lung cancer[J]. J Thorac Oncol, 2016, 11 (7): 976-88. doi: 10.1016/j.jtho.2016.02.015 [16] Li D, Cheng SY, Zou SJ, et al. Immuno-PET imaging of 89Zr labeled anti-PD-L1 domain antibody[J]. Mol Pharm, 2018, 15(4): 1674-81. doi: 10.1021/acs.molpharmaceut.8b00062 [17] Donnelly DJ, Smith RA, Morin P, et al. Synthesis and biologic evaluation of a novel 18F-labeled adnectin as a PET radioligand for imaging PD-L1 expression[J]. J Nucl Med, 2018, 59(3): 529-35. doi: 10.2967/jnumed.117.199596 [18] Chatterjee S, Lesniak WG, Nimmagadda S. Noninvasive imaging of immune checkpoint ligand PD-L1 in tumors and metastases for guiding immunotherapy[J]. Mol Imaging, 2017, 16: 1536012117718459. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676497/ [19] Ilovich O, Natarajan A, Hori S, et al. Development and validation of an immuno-PET tracer as a companion diagnostic agent for antibody-drug conjugate therapy to target the CA6 epitope[J]. Radiology, 2015, 276(1): 191-8. doi: 10.1148/radiol.15140058 [20] Kumar D, Lisok A, Dahmane E, et al. Peptide-based PET quantifies target engagement of PD-L1 therapeutics[J]. J Clin Invest, 2019, 129 (2): 616-30. doi: 10.1172/JCI122216 [21] Lindner JR, Link J. Molecular imaging in drug discovery and development[J]. Circ Cardiovasc Imaging, 2018, 11(2): e005355. http://europepmc.org/abstract/MED/29449411 [22] Sachpekidis C, Anwar H, Winkler J, et al. The role of interim 18FFDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma[J]. Eur J Nucl Med Mol Imaging, 2018, 45(8): 1289-96. doi: 10.1007/s00259-018-3972-9 [23] Anwar H, Sachpekidis C, Winkler J, et al. Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab[J]. Eur J Nucl Med Mol Imaging, 2018, 45(3): 376-83. doi: 10.1007/s00259-017-3870-6 [24] Fu RS, Carroll L, Yahioglu G, et al. Antibody fragment and affibody ImmunoPET imaging agents: radiolabelling strategies and applications[J]. ChemMedChem, 2018, 13(23): 2466-78. doi: 10.1002/cmdc.201800624 [25] Wu AM. Antibodies and antimatter: the resurgence of immuno-PET [J]. J Nucl Med, 2008, 50(1): 2-5. doi: 10.2967/jnumed.108.056887 [26] Van Dijk LK, Boerman OC, Kaanders JH, et al. PET imaging in head and neck cancer patients to monitor treatment response: a future role for EGFR-targeted imaging[J]. Clin Cancer Res, 2015, 21(16): 3602-9. doi: 10.1158/1078-0432.CCR-15-0348 [27] Menke-van der Houven van Oordt CW, Gootjes EC, Huisman MC, et al. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer[J]. Oncotarget, 2015, 6(30): 30384-93. doi: 10.18632/oncotarget.4672 [28] O'Donoghue JA, Smith-Jones PM, Humm JL, et al. 124I- huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET[J]. J Nucl Med, 2011, 52(12): 1878-85. doi: 10.2967/jnumed.111.095596 [29] Truillet C, Oh HLJ, Yeo SP, et al. Imaging PD-L1 expression with ImmunoPET[J]. Bioconjug Chem, 2018, 29(1): 96-103. doi: 10.1021/acs.bioconjchem.7b00631 [30] Wu NJ, Kang CS, Sin I, et al. Promising bifunctional chelators for copper 64-PET imaging: practical (64)Cu radiolabeling and high in vitro and in vivocomplex stability[J]. J Biol Inorg Chem, 2016, 21 (2): 177-84. doi: 10.1007/s00775-015-1318-7 [31] Chatterjee S, Lesniak WG, Gabrielson M, et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors[J]. Oncotarget, 2016, 7(9): 10215-27. doi: 10.18632/oncotarget.7143 [32] Jauw YWS, O'Donoghue JA, Zijlstra JM, et al. 89Zr-immuno-PET: toward a noninvasive clinical tool to measure target engagement of therapeutic antibodies in vivo[J]. J Nucl Med, 2019, 60(12): 1825-32. doi: 10.2967/jnumed.118.224568 [33] Christensen C, Kristensen LK, Alfsen MZ, et al. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody[J]. Eur J Nucl Med Mol Imaging, 2020, 47(5): 1302-13. doi: 10.1007/s00259-019-04646-4 [34] Jagoda EM, Vasalatiy O, Basuli F, et al. Immuno-PET imaging of the programmed cell death-1 ligand (PD-L1) using a zirconium-89 labeled therapeutic antibody, avelumab[J]. Mol Imaging, 2019, 18: 1536012119829986. http://www.researchgate.net/publication/332805678_Immuno-PET_Imaging_of_the_Programmed_Cell_Death-1_Ligand_PD-L1_Using_a_Zirconium-89_Labeled_Therapeutic_Antibody_Avelumab/download [35] Lesniak WG, Chatterjee S, Gabrielson M, et al. PD-L1 detection In tumors using[(64)Cu]atezolizumab with PET[J]. Bioconjug Chem, 2016, 27(9): 2103-10. doi: 10.1021/acs.bioconjchem.6b00348 [36] Bensch F, van der Veen EL, Lub-de Hooge MN, et al. 89Zratezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer[J]. Nat Med, 2018, 24(12): 1852-8. doi: 10.1038/s41591-018-0255-8 [37] Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients [J]. Nature, 2014, 515(7528): 563-7. doi: 10.1038/nature14011 [38] Maute RL, Gordon SR, Mayer AT, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging[J]. Proc NatlAcad Sci USA, 2015, 112(47): E6506-14. doi: 10.1073/pnas.1519623112 [39] Olafsen T, Wu AM. Antibody vectors for imaging[J]. Semin Nucl Med, 2010, 40(3): 167-81. doi: 10.1053/j.semnuclmed.2009.12.005 [40] Wissler HL, Ehlerding EB, Lyu Z, et al. Site-specific immuno-PET tracer to image PD-L1[J]. Mol Pharm, 2019, 16(5): 2028-36. doi: 10.1021/acs.molpharmaceut.9b00010 [41] Könning D, Zielonka S, Grzeschik J, et al. Camelid and shark single domain antibodies: structural features and therapeutic potential[J]. Curr Opin Struct Biol, 2017, 45: 10-6. doi: 10.1016/j.sbi.2016.10.019 [42] Lv G, Sun XR, Qiu L, et al. PET imaging of tumor PD-L1 expression with a highly specific nonblocking single- domain antibody[J]. J Nucl Med, 2020, 61(1): 117-22. doi: 10.2967/jnumed.119.226712 [43] de Silva RA, Kumar D, Lisok A, et al. Peptide-based 68Ga-PET radiotracer for imaging PD-L1 expression in cancer[J]. Mol Pharm, 2018, 15(9): 3946-52. doi: 10.1021/acs.molpharmaceut.8b00399 [44] Chatterjee S, Lesniak WG, Miller MS, et al. Rapid PD-L1 detection in tumors with PET using a highly specific peptide[J]. Biochem Biophys Res Commun, 2017, 483(1): 258-63. doi: 10.1016/j.bbrc.2016.12.156 -
点击查看大图
表(1)
计量
- 文章访问数: 580
- HTML全文浏览量: 216
- PDF下载量: 13
- 被引次数: 0
